Kornimate/medical-research-clean huggingface dataset:
human intestinal amino acid absorption and the role of a local (renin)-angiotensin system (ras)

Conditions: Healthy Participants; Hypertension

Summary: aim of this trial is to investigate the expression and localisation of different amino acid transporters and their regulatory proteins derived from the regulatory proteins of the local renin angiotensin system (ras) in the intestine. this is investigated on one hand in patients who do not take any drugs interfering with ras. on the other hand expression analysis is done in patients taking daily ras-active drugs, like ace inhibitors or sartanes. after obtaining informed consent of patients attending the hospital for clarification of gastrointestinal symptoms by gastroduodenoscopy or colonoscopy, 2 biopsies (in addition to biopsies needed for clinical diagnostics) will be taken from each duodenum, jejunum, ileum and descending colon. biopsies are investigated anonymously at the institute of physiology of the university of zurich. the mrna content of amino acid transporters and regulatory proteins, respectively, in the biopsies is analyzed by quantitative pcr. transport proteins are in addition analyzed with immunohistochemistry. furthermore amino acid concentration in plasma and urine samples are analyzed by hplc. from plasma and serum samples ras parameters like renin, aldosterone, ace and angiotensin(1-7) are measured.


Eligibility criteria:
inclusion criteria: * men and women aged 18-80 years * bmi 18-35 kg/m2 * group 1: patients taking daily ras-active drugs, like ace inhibitors or sartanes (treatment indication outside of this study) * group 2: no therapy with ras-active drugs, like ace inhibitors or sartanes gastroduodenoscopy and/or colonoscopy with a treatment indication outside of this study * informed consent exclusion criteria: * severe pathologic alterations in the gastrointestinal tract (ulcers, tumors, celiac disease; gerd and gastritis are no exclusion criteria) * status after operations of the gastrointestinal tract (except uncomplicated appendectomy or inguinal hernia repair) * patients with malignant diseases * severe acute or chronic diseases which require treatment (e.g. renal replacement therapy) * patients with increased bleeding risk (e.g. oral anticoagulation, coagulopathy) * drug or alcohol abuse * mental disorders which limits the ability to fulfil all study requirements
effect of an electronic reminder system on direct oral anticoagulant and oral diabetes medication adherence

Conditions: Anticoagulant Drugs; Diabetes Mellitus, Type 2

Summary: in this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.

in this study study two different groups of medicine users are recruited. both groups have 50 patients each. in the first study the participants are using oral medication for diabetes and in the second study the participants use new direct oral anticoagulants. participants use medicine reminder system consisting of an electronic device and an smart phone application. in the beginning of the study the reminder system is collecting data on how the patients are taking their medication for the first two months. smart phone application is not providing any reminders and participants can't access the app to see the details. after two months the application will be unlocked so that it starts reminding the users to take their medication at the right time. in this phase the patients can view their medication data from the application. the reminder phase of the study lasts for two months. after these two plus two months, the results are analyzed and published. the study continues after these four months for the next four months and after that, the long term results are analyzed.' the primary outcome is the possible change in the adherence between control and active period.

Eligibility criteria:
inclusion criteria: * use of direct oral anticoagulants or oral diabetic drugs * age of 18 or more * subjects have been using a smart phone exclusion criteria: * patients who don't use their medication without help

Keywords: medicine reminder diabetes mellitus, type 2 direct oral anticoagulants
extension study of mavacamten (myk-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy previously enrolled in pioneer

Conditions: Hypertrophic Cardiomyopathy

Summary: this is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive hcm (ohcm) who previously participated in study myk-461-004 (pioneer-hcm).


Eligibility criteria:
key inclusion criteria: * completed study myk-461-004. prior participation in a non-interventional observational study is allowed. * body weight \> 45 kg at screening * has safety laboratory parameters (chemistry and hematology) within normal limits key exclusion criteria: * has qtcf \> \> 500 ms or any other ecg abnormality considered by the investigator to pose a risk to subject safety (eg, second degree atrioventricular block type ii) * since enrollment into study myk-461-004, has developed obstructive coronary artery disease (\> 70% stenosis in one or more arteries) or known moderate or severe aortic valve stenosis * since enrollment into study myk-461-004, has developed any acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the opinion of the investigator or medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion * since enrollment into study myk-461-004 has developed clinically significant malignant disease

Keywords: symptomatic obstructive left ventricular outflow tract gradient
the impact of rituximab in patients with primary breast diffuse large b cell lymphoma (dlbcl)

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: the purpose of this study is to investigate the impact of rituximab in primary breast dlbcl using a matched pair analysis following strict matching criteria in patients with primary breast and nodal dlbcl treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) regimen.

primary breast lymphoma represents 1.7% to 2.2% of all extranodal non-hodgkin's lymphoma. histologically, the diffuse large b cell lymphoma (dlbcl) is the most predominant subtype of pbl. previous studies in the pre-rituximab era have identified the worse outcomes in primary breast dlbcl compared with nodal dlbcl. few clinical studies have been reported for investigating the efficacy of rituximab in patients with primary breast dlbcl. for clarifying this, a large randomized trial comparing survival in patients with primary breast dlbcl is required. however, the rarity of primary breast dlbcl makes large trial virtually difficult in single center or study group. additionally, retrospective studies for evaluating the role of rituximab in primary breast dlbcl had bias according to the difference of treatment period between chop and r-chop era. thus, in attempt to clarify the impact of rituximab on survival and patterns of progression in patients with primary breast dlbcl, the investigators performed this matched pair analysis following strict matching criteria in patients with primary breast dlbcl, who were identified from our previous nation-wide survey, and nodal dlbcl, who were selected from the data registry of korean society of hematology lymphoma working party, treated with r-chop regimen.

Eligibility criteria:
inclusion criteria: * stage i or ii of primary breast dlbcl treated with r-chop * stage i or ii of nodal dlbcl treated with r-chop definition of primary breast dlbcl - isolated breast involvement with or without nodal disease, which include distant nodal disease as well as regional nodal disease definition of nodal dlbcl - the disease was only limited to the lymph nodes or lymphoid organs exclusion criteria: * primary breast dlbcl or nodal dlbcl treated without rituximab * secondary breast dlbcl * recurrent dlbcl * stage iii or iv of nodal dlbcl with extranodal involvement as a dissemination process

Keywords: diffuse large b cell lymphoma breast rituximab
the value of myomectomy in women with intramural myoma before ivf.

Conditions: Fibroid Uterus; IVF

Summary: women with intramural myoma not reaching the endometrial cavity will be randomized to either open myomectomy or no intervention . the participants will be assessed through full history-taking with special consideration to age and the duration, type, and cause of infertility. the medical examination included general, abdominal, and vaginal examinations. finally, an ultrasonography examination was performed to check for the presence of three or more preantral follicles and to exclude ovarian cysts. on day 3 of a natural cycle, a baseline levels of fsh, luteinizing hormone (lh), , estradiol and anti-müllerian hormone (amh).ovarian stimulation was performed using a long, antagonist, or short protocol. they were assigned to one of the 2 groups according to having an intramural myoma not indenting the cavity or not. all will be followed up by transvaginal ultrasonography . when two or more follicles had reached a mean diameter of 18 mm, oocyte maturation was triggered by intramuscular administration of hcg. embryo transfer will be done at day 2, 3 or 5 according to the circumstances.

women with intramural myoma not reaching the endometrial cavity will be randomized to either open myomectomy or no intervention .the participants will be assessed through full history-taking with special consideration to age and the duration, type, and cause of infertility. the medical examination included general, abdominal, and vaginal examinations. finally, an ultrasonography examination was performed to check for the presence of three or more preantral follicles and to exclude ovarian cysts. on day 3 of a natural cycle, a baseline levels of fsh, luteinizing hormone (lh), , estradiol and anti-müllerian hormone (amh).ovarian stimulation was performed using a long, antagonist, or short protocol. they were assigned to one of the 2 groups according to having an intramural myoma not indenting the cavity or not. all will be followed up by transvaginal ultrasonography . when two or more follicles had reached a mean diameter of 18 mm, oocyte maturation was triggered by intramuscular administration of hcg. embryo transfer will be done at day 2, 3 or 5 according to the circumstances.

Eligibility criteria:
inclusion criteria: * • age younger than 40 years * fsh) less than 10 iu/l * serum prolactin level normal * uterine cavity abnormality was excluded by hysteroscopy or hysterosalpingography exclusion criteria: * abnormal endocrine function (e.g. abnormal thyroid or adrenal function) * ovarian cysts, * hydrosalpinx * endometrial polyps * male partner with azoospermia * icsi performed for preimplantation genetic diagnosis.
comparison of function and fit of standard and gender-specific cr high-flex total knee prostheses

Conditions: Osteoarthritis

Summary: the purpose of this prospective, randomized study was to compare functional outcome, radiographic results, range of motion, patients satisfaction, and fit of the femoral component in patients receiving either a standard posterior cruciate-retaining high-flexion (cr-flex) and gender-specific cr-flex total knee prostheses.

the design features of the gender-specific knee prostheses have been claimed to improve fit and function of total knee arthroplasty in women. the purpose of this prospective, randomized study was to compare functional outcome, radiographic results, range of motion, patients satisfaction, and fit of the femoral component in patients receiving either a standard posterior cruciate-retaining high-flexion (cr-flex) and gender-specific cr-flex total knee prostheses.

Eligibility criteria:
inclusion criteria: * end stage osteoarthritis of the knee joint who require total knee arthroplasty with bilateral lesions. exclusion criteria: * inflammatory arthritis * osteoarthritis effecting hip joint * traumatic arthritis * neurologic disorders affecting motor function of lower extremity * foot and ankle disorders limiting ambulation of the patient

Keywords: gender specific cruciate retaining total knee arthroplasty bilateral osteoarthritis of the knee joint
causal relationship between plasma vegf family proteins and placenta previa: a two-sample mendelian randomization study

Conditions: Placenta Previa

Summary: this study aims to investigate the causal relationship between plasma vascular endothelial growth factor (vegf) family proteins and placenta previa using a two-sample mendelian randomization (mr) approach. genome-wide association study (gwas) data will be analyzed to assess the correlation and potential causality between vegf protein levels and the occurrence of placenta previa.

placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. this study utilizes mendelian randomization (mr) to explore the potential causal link between plasma levels of vegf family proteins (including vegfa, vegfb, vegfc, vegfd, and plgf) and the risk of placenta previa. by using genome-wide association study (gwas) data from the uk biobank and finngen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. the mr analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between vegf proteins and placenta previa.

Eligibility criteria:
inclusion criteria: * participants included in genome-wide association studies (gwas) with available data on plasma vegf family proteins and placenta previa. exclusion criteria: * participants with incomplete or missing data on plasma vegf levels or placenta previa.

Keywords: vascular endothelial growth factor (vegf) mendelian randomization angiogenesis pregnancy complications placental development
fidaxomicin to prevent clostridium difficile colonization

Conditions: Clostridium Difficile Infection

Summary: the purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing c. difficile infection.

a novel approach to prevent c. difficile infection is to use compounds with activity against c. difficile as primary prophylaxis in high risk patients. chemoprophylaxis theoretically can prevent c. difficile infection by two mechanisms. it may reduce transmission from asymptomatic c. difficile carriers by reducing the number of spores shed in the stool and prevent replication and subsequent toxin production of the organisms in patients at risk for c. difficile infection.

Eligibility criteria:
inclusion criteria: * ≥ 18 years old * on broad spectrum antimicrobials * anticipated length of stay of \> 48 hours after enrollment * a non-icu inpatient exclusion criteria: * pregnant * expected to die within 7 days * have previously been enrolled in this trial or a trial of an investigational agent to treat cdi, and/or are on monotherapy with an antimicrobial generally considered not to increase the risk of cdi (vanc, macrolides, tetracyclines, trimethoprim/sulfamethoxazole, aminoglycosides, colistin, linezolid, nitrofurantoin, metronidazole)

Keywords: clostridium difficile infection fidaxomicin
study of emu oil vs. placebo for vulvar pain in women.

Conditions: Vulvodynia; Vestibulodynia

Summary: the goal of this study is to determine if vulvar (external female genitalia) pain is decreased with emu oil over a similar placebo oil (no active ingredient) by using measurement devices, examinations, and questionnaires. topical emu oil has not been scientifically studied for this condition yet, but related reports show no significant side effects or potential benefits. a total of 30 women will participate in the study at william beaumont hospital, royal oak.

* women of all ages with vulvar pain may participate in this trial. * women will be randomized into 2 groups--a treatment group or placebo group for the 1 month study. * at the end of the study, those in the placebo group may choose to participate in a 1 month follow-up evaluation using emu oil.

Eligibility criteria:
inclusion criteria: * women with vulvar pain upon q-tip exam of \> 3/10 at 2 or more sites tested. * age 18 or older. * capable of giving informed consent. * capable and willing to follow all study procedures. exclusion criteria: * pregnant women or those intending to become pregnant during the study period. * vaginitis (may be treated, then tested later). * vulvar disease (other than vulvodynia)-lichen planus, lichen sclerosis, neoplasia, tissue damage due to radiation. * the subject is deemed unsuitable for enrollment by the investigators based on their history or physical examination. * neuropathy. * currently in pelvic floor physical therapy.

Keywords: vulvar pain vulvodynia vestibulodynia vulvar vestibulitis
ganciclovir pharmacokinetics in patients undergoing continuous renal replacement therapy

Conditions: Acute Renal Failure; Cytomegalovirus Infections; Multi Organ Failure

Summary: in order to optimize anti-cytomegalovirus (cmv) treatment with ganciclovir (gcv), in patients with multi organ failure treated with continuous renal replacement therapy (rrt), more information about ganciclovir pharmacokinetics in this setting is needed. the primary objective is to describe the pharmacokinetics of ganciclovir in critically ill patients with acute renal failure treated with continuous renal replacement therapy, with a special emphasis on the extra-renal clearance and distribution volume. secondary objectives are to investigate if any co-factors, such as serum creatinine, weight, general hydration status, rest function of the native kidneys, etc. can help to describe the pharmacokinetics of gcv in these patients on continuous rrt as well as the relative influence of filtrations and dialysis on gcv elimination during different modalities of the treatment.


Eligibility criteria:
inclusion criteria: * patients in need of continuous rrt and gcv treatment * 18 years of age or older. exclusion criteria: * concomitant treatment with acyclovir or valacyclovir. * patient does not give informed consent.

Keywords: renal replacement therapy cmv disease
validation of the sentinel lymph node technique in early-stage ovarian cancer (sentov ii)

Conditions: Ovarian Neoplasms

Summary: this clinical trial investigates the sentinel lymph node (sln) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. the primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the sln approach in detecting lymphatic metastases. by assessing its negative predictive value, the study aims to determine whether the sln technique can reliably replace systematic pelvic and paraaortic lymphadenectomy. if successful, this technique could minimize surgical morbidity, shorten hospitalization stays, and lower complication rates, ultimately improving patient outcomes.


Eligibility criteria:
inclusion criteria: * signed informed consent prior to the performance of any procedure related to the clinical trial. * female, 18 years of age or older at the time of inclusion. * patients with a histopathological diagnosis of malignant ovarian tumor in a deferred study (any epithelial histology), in apparent early stage figo i-ii, proposed for staging surgery, or patients with suspected malignant ovarian tumor in apparent early stage figo i-ii, who will undergo exploratory laparotomy and operative biopsy, and if positive, will undergo staging surgery. exclusion criteria: * failure to obtain informed consent or revocation of informed consent. * under 18 years of age at the time of inclusion. * previous history of vascular surgery on the aorta, vena cava, or pelvic vessels. * previous pelvic or paraaortic lymphatic surgery. * previous lymphoma. * previous abdomino-pelvic tumor. * previous allergy to tc99 or icg. * pregnancy/breastfeeding. patients who have signed informed consent but do not meet all inclusion criteria and none of the exclusion criteria will be considered as selection failures.

Keywords: sentinel node technique
gastroesophageal varices in cavernoma

Conditions: Gastroesophageal Varices; Myeloproliferative Neoplasm; Portal Caver Cavernoma; Portal Hypertension

Summary: myeloproliferative neoplasms (mpns), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. the quality of life, morbidity, and mortality of mpn patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. previous studies have shown that jak2 v617f has a prominent role in vascular risk and mpn-associated gastroesophageal varices. portal vein thrombosis and portal cavernoma frequently occur in the mpn population and the management of gastroesophageal varices in these patients are sometimes technically difficult. the aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without jak2 mutation.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18-75 * diagnosed as portal hypertension and portal cavernoma by contrast-enhanced computed tomography * underwent jak2 mutation test exclusion criteria: * combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease. * other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.

Keywords: portal hypertension gastroesophageal varices jak2 mutation myeloproliferative neoplasm portal caver cavernoma
evaluating an internet-based intervention for insomnia in breast cancer survivors

Conditions: Insomnia; Breast Cancer

Summary: this study examines the efficacy of an internet-delivered intervention to reduce symptoms of insomnia in breast cancer survivors. breast cancer patients with insomnia (n=30) will be assigned to either gain access to the 6-week treatment program immediately (experimental group) or following study participation (control group).


Eligibility criteria:
inclusion criteria: * female * diagnosed with breast cancer * age 18 and older * completed primary treatment at least one month prior to enrollment * diagnosis of insomnia exclusion criteria: * experiencing a sleep disorder other than insomnia (e.g., sleep apnea) * experiencing a major depressive episode or other serious psychiatric disturbance * modification of psychotropic medications within the previous month * undergoing current psychotherapy treatment

Keywords: insomnia breast cancer survivor internet intervention